NASDAQ: RKTORocket One Inc Stock
$1.46-0.24 (-14.12%)
Updated May 29, 2026
RKTO Price
$1.46
Fair Value Price
$0.45
Market Cap
$27.93M
52 Week Low
$0.49
52 Week High
$2.20
P/E
-1.83x
P/B
6.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.69M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.34
Operating Cash Flow
-$10M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RKTO Overview
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RKTO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RKTO
Ranked#388 of 467
Ranked#388 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.49 | A | |
| $50.48 | A | |
| $15.33 | A |
Be the first to know about important RKTO news, forecast changes, insider trades & much more!
RKTO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RKTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RKTO ($1.46) is overvalued by 222.93% relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RKTO ($1.46) is not significantly undervalued (222.93%) relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RKTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RKTO due diligence checks available for Premium users.
Valuation
RKTO fair value
Fair Value of RKTO stock based on Discounted Cash Flow (DCF)
Price
$1.46
Fair Value
$0.45
Overvalued by
222.93%
RKTO ($1.46) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RKTO ($1.46) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RKTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RKTO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.83x
Industry
15.12x
Market
23.22x
RKTO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.71x
Industry
4.94x
RKTO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RKTO's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.7M
Profit Margin
0%
RKTO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.6M
Liabilities
$1.4M
Debt to equity
0.34
RKTO's short-term assets ($4.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RKTO's short-term assets ($4.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RKTO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RKTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$147.2k
Financing
$701.5k
RKTO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RKTO vs Biotech Stocks
Rocket One Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.